The European Medicines Agency (EMA) and the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) have announced an agreement that will enable the parties to share confidential information on COVID-19 medicines.
The European Medicines Agency (EMA) and the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) have announced an agreement that will enable the parties to share confidential information on COVID-19 medicines.
According to a June 30, 2020 press release, the agreement is an ad-hoc arrangement, exclusively focused on medicines intended for the treatment, diagnosis, or prevention of COVID-19. This latest arrangement works harmoniously with EMA’s other confidential agreements with other countries and organizations.
The strategic coordination between global regulators will be managed by the International Coalition of Medicines Regulatory Authorities (ICMRA), which is chaired by EMA. To enable various regulatory authorities to discuss related COVID-19 work, ICMRA is holding bi-weekly meetings in the hope that medicine and vaccine development will be expedited.
